

GlaxoSmithKline Nigeria Plc 9M 2021 15 November 2021 MPR: 11.50%

MPR: 11.50% Sept '21 Inflation Rate: 16.63% Q2 2021 Real GDP: 5.01%

GlaxoSmithKline Consumer Nigeria PLC Statement of Profit or Loss			9M 20 (N')	021 Mn)	9M 20 (N'A	-	% Change
Revenue				16,452.58		16,447.21	
Cost of Sales				(12,084.20)		(12,028.94)	
Gross Profit				4,368.38		4,418.27	
Investment income			49	49.28		63.04	
Other gains and losses			82	82.09		64.17	
Selling and Distribution expenses			(2,748	(2,748.23)		(2,493.29)	
Administrative expenses			(1,565	(1,565.76)		(1,413.48)	
Profit from operating activities			185	185.77		.71	- 70.9 1%
Finance Income			C	0.00		.00	
Finance costs			(4	(4.44)		.00	
Net Finance Costs			(4	(4.44) 0.00		.00	
Loss/Profit before tax			181	1.33	638.71		-71.61%
Income tax credit/(expense)			(58	.63)	(204.39)		-71.31%
Loss/Profit after tax			122	2.70	434.32		-71.75%
Basic Earnings	per Share	(in Kobo)	10	0.00	36	.00	-72.22%
Balance Sheet as at September 30, 2021			30-Sep-2	30-Sep-2021 31-Dec-202		020	
Cash and cash equivalents			10,136	6.72 12,896.74		.74	-21.40%
Trade and other receivables			5,876	,876.42 4,649.95		.95	26.38%
Inventories			4,820	4,820.72		.44	46.86%
Property Plant and Equipment			1,729	1,729.17		1,830.99	
Other Assets			930	930.64		1,075.70	
Total Assets			23,493	23,493.66		23,735.82	
Trade and other payables			14,708	14,708.99		13,765.41	
Current tax liabilities			59	59.95		105.61	
Deferred tax liabilities			(0.00		0.00	
Borrowings			(0.00		11.16	
Other Liabilities			131	131.36		906.52	
Total Liabilities			14,900.30		14,788.69		-85.51% 0. 75 %
Total shareholders' equity urce: Company Financials, Cowry Research			8,593	8,593.37		8,947.13	
-inal Dividend	Bonus	Qualification Date	Closure Date	Closure Date Payment Date N/A N/A		AG	M Date
N/A	N/A	N/A	N/A			N/A	

IMPORTANT DISCLOSURES: This report is produced by the Research Desk, Cowry Asset Management Limited (COWRY) as a guideline for Clients that intend to invest in securities on the basis of their own investment decision without relying completely on the information contained herein. The opinion contained herein is for information purposes only and does not constitute any offer or solicitation to enter into any trading transaction. While care has been taken in preparing this document, no responsibility or liability whatsoever is accepted by any member of COWRY for errors, omission of facts, and any direct or consequential loss arising from the use of this report or its contents.